• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
187974 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
" S2 q3 O# w7 L3 b( @+ E6 V
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
# {' z2 ^' D5 g. Y0 e! f7 {3 G* \7 J5 Q, [, S) W! F2 Z0 l
1 I& H: F: T! M. X$ j
Sub-category:7 N# E+ A3 `4 Y& s
Molecular Targets   {9 N6 M9 @+ u- X7 r, j
+ Q( g6 S4 T6 r8 C3 D6 J  L4 m; h
# }# y6 J/ W8 y8 y
Category:& e% O1 Q2 c! ~1 F( x4 m+ w% a: |3 A3 I
Tumor Biology 5 R6 ?" Q5 p+ s3 k+ n: ^
( M- U3 h7 L5 r/ ~4 ?4 c5 \$ e
& j  r- r5 U( ]: b! U8 a2 u2 W
Meeting:
2 y2 @/ ^8 _3 L# J3 r" h9 g! _# \2011 ASCO Annual Meeting 8 L# v* a* e8 n# g0 o1 Z

( U. G' V0 _5 l& i0 t8 p0 d1 Y, ^
Session Type and Session Title:, V/ c( D: W4 a0 ]: k6 g
Poster Discussion Session, Tumor Biology
/ ]( S6 C( }8 K8 E7 Z6 R. ~5 f0 A+ n2 e+ Y2 ]
1 f& [. L% O2 X  K6 X
Abstract No:, ~: x1 D( g- M* E7 T6 u/ U
10517
5 u9 B! v8 o+ d4 c: E, Q! M  z' S- ~

& B- V7 P7 {3 ?7 d5 a! P, e4 uCitation:
- U. X7 I9 h6 \, r5 V7 UJ Clin Oncol 29: 2011 (suppl; abstr 10517)
, \+ M/ G( [9 C% S' Y) j* w0 `" f
' r( y, B5 o' z; D. l
4 K; K0 b2 F  ]9 LAuthor(s):
" O0 b4 ^. K! ]0 q' s1 ZJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
# Q! B3 ?8 s( ]. u5 S/ K2 f: W. n& R( K9 J' F% E
1 n2 q0 X3 q4 V

& @) [. s. ?% m6 mAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.! d8 V5 B! ]1 F; e% z

( W# p( W* ^, N( Y! W1 m1 nAbstract Disclosures. [! ?. T$ J6 a  ~; n5 C
/ Q# M6 k1 |4 X5 j: T. w) n; a4 u
Abstract:! W# Y* _' q$ m$ ~/ J6 h) D

) x$ J4 j1 \. j7 G, a9 {
2 Q) O+ O: \5 E& M2 aBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.7 g* _2 Z9 h4 A8 g8 j
3 t4 m& Q& y* R; ]* u6 p1 d( _, r
# A2 D# ^- `+ A  T) x+ y, e
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
  o1 [- x- ?, m- H" s8 N4 j没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

4 S% s% P0 C; Z: ~$ s) A1 J4 G8 ]化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20   m' q0 r9 N$ m) P: X! [# ], o
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。- d1 r- c+ J3 J* X- k4 L# I4 x& p
ALK一个指标医院要900多 ...
* _9 K0 U( B; y: c
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?9 z+ E0 v1 }9 l, u5 g
' j) A( c1 h( [6 P0 x/ z6 W
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表